IBDEI374 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,51026,0)
 ;;=N30.90^^193^2499^20
 ;;^UTILITY(U,$J,358.3,51026,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51026,1,3,0)
 ;;=3^Cystitis w/o Hematuria,Unspec
 ;;^UTILITY(U,$J,358.3,51026,1,4,0)
 ;;=4^N30.90
 ;;^UTILITY(U,$J,358.3,51026,2)
 ;;=^5015642
 ;;^UTILITY(U,$J,358.3,51027,0)
 ;;=N41.9^^193^2499^38
 ;;^UTILITY(U,$J,358.3,51027,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51027,1,3,0)
 ;;=3^Inflammatory Disease of Prostate,Unspec
 ;;^UTILITY(U,$J,358.3,51027,1,4,0)
 ;;=4^N41.9
 ;;^UTILITY(U,$J,358.3,51027,2)
 ;;=^5015694
 ;;^UTILITY(U,$J,358.3,51028,0)
 ;;=N70.91^^193^2499^75
 ;;^UTILITY(U,$J,358.3,51028,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51028,1,3,0)
 ;;=3^Salpingitis,Unspec
 ;;^UTILITY(U,$J,358.3,51028,1,4,0)
 ;;=4^N70.91
 ;;^UTILITY(U,$J,358.3,51028,2)
 ;;=^5015806
 ;;^UTILITY(U,$J,358.3,51029,0)
 ;;=N70.93^^193^2499^74
 ;;^UTILITY(U,$J,358.3,51029,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51029,1,3,0)
 ;;=3^Salpingitis & Oophoritis,Unspec
 ;;^UTILITY(U,$J,358.3,51029,1,4,0)
 ;;=4^N70.93
 ;;^UTILITY(U,$J,358.3,51029,2)
 ;;=^5015808
 ;;^UTILITY(U,$J,358.3,51030,0)
 ;;=N70.92^^193^2499^55
 ;;^UTILITY(U,$J,358.3,51030,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51030,1,3,0)
 ;;=3^Oophoritis,Unspec
 ;;^UTILITY(U,$J,358.3,51030,1,4,0)
 ;;=4^N70.92
 ;;^UTILITY(U,$J,358.3,51030,2)
 ;;=^5015807
 ;;^UTILITY(U,$J,358.3,51031,0)
 ;;=N73.9^^193^2499^37
 ;;^UTILITY(U,$J,358.3,51031,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51031,1,3,0)
 ;;=3^Inflammatory Disease Female Pelvic,Unspec
 ;;^UTILITY(U,$J,358.3,51031,1,4,0)
 ;;=4^N73.9
 ;;^UTILITY(U,$J,358.3,51031,2)
 ;;=^5015820
 ;;^UTILITY(U,$J,358.3,51032,0)
 ;;=A56.11^^193^2499^36
 ;;^UTILITY(U,$J,358.3,51032,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51032,1,3,0)
 ;;=3^Inflammatory Disease Chlamydial Female Pelvic
 ;;^UTILITY(U,$J,358.3,51032,1,4,0)
 ;;=4^A56.11
 ;;^UTILITY(U,$J,358.3,51032,2)
 ;;=^5000342
 ;;^UTILITY(U,$J,358.3,51033,0)
 ;;=N73.5^^193^2499^64
 ;;^UTILITY(U,$J,358.3,51033,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51033,1,3,0)
 ;;=3^Peritonitis Female Pelvic,Unspec
 ;;^UTILITY(U,$J,358.3,51033,1,4,0)
 ;;=4^N73.5
 ;;^UTILITY(U,$J,358.3,51033,2)
 ;;=^5015817
 ;;^UTILITY(U,$J,358.3,51034,0)
 ;;=N72.^^193^2499^35
 ;;^UTILITY(U,$J,358.3,51034,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51034,1,3,0)
 ;;=3^Inflammatory Disease Cervix Uteri
 ;;^UTILITY(U,$J,358.3,51034,1,4,0)
 ;;=4^N72.
 ;;^UTILITY(U,$J,358.3,51034,2)
 ;;=^5015812
 ;;^UTILITY(U,$J,358.3,51035,0)
 ;;=N76.3^^193^2499^92
 ;;^UTILITY(U,$J,358.3,51035,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51035,1,3,0)
 ;;=3^Vulvitis,Subacute & Chronic
 ;;^UTILITY(U,$J,358.3,51035,1,4,0)
 ;;=4^N76.3
 ;;^UTILITY(U,$J,358.3,51035,2)
 ;;=^5015829
 ;;^UTILITY(U,$J,358.3,51036,0)
 ;;=N76.1^^193^2499^88
 ;;^UTILITY(U,$J,358.3,51036,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51036,1,3,0)
 ;;=3^Vaginitis,Subacute & Chronic
 ;;^UTILITY(U,$J,358.3,51036,1,4,0)
 ;;=4^N76.1
 ;;^UTILITY(U,$J,358.3,51036,2)
 ;;=^5015827
 ;;^UTILITY(U,$J,358.3,51037,0)
 ;;=N76.2^^193^2499^91
 ;;^UTILITY(U,$J,358.3,51037,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51037,1,3,0)
 ;;=3^Vulvitis,Acute
 ;;^UTILITY(U,$J,358.3,51037,1,4,0)
 ;;=4^N76.2
 ;;^UTILITY(U,$J,358.3,51037,2)
 ;;=^5015828
 ;;^UTILITY(U,$J,358.3,51038,0)
 ;;=N76.0^^193^2499^87
 ;;^UTILITY(U,$J,358.3,51038,1,0)
 ;;=^358.31IA^4^2
